Drug inhibition of angiogenesis

Current Opinion in Pharmacology

Volumn 2, Issue 4, 2002, Pages 403-414

  Madhusudan, Srinivasan ^a   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; MONOCLONAL ANTIBODY; TYROSINE TRANSFER RNA LIGASE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ARTICLE; CANCER; CANCER THERAPY; CARCINOGENESIS; CONTROLLED STUDY; DRUG DESIGN; DRUG INHIBITION; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; ANIMAL; CLASSIFICATION; DRUG DELIVERY SYSTEM; METABOLISM; METHODOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0036667393     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00184-4     Document Type: Review

References (99)

1. Tumor angiogenesis: Past, present and the near future
2. Angiogenesis: Pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs
3. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies
4. Is angiogenesis inhibition the Holy Grail of cancer therapy?
5. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
6. Industrial-scale, genomics-based drug design and discovery
7. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation
8. The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor
9. The hemostatic system as a regulator of angiogenesis
10. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF
11. Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility
12. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells
13. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors
14. Angiogenesis inhibitors revised and revived at AACR
15. Clinical trials of antiangiogenic drugs: Opportunities, problems, and assessment of initial results
16. New functions for the matrix metalloproteinases in cancer progression
17. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
18. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
19. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MM1270 (CGS27023A), in patients with advanced solid cancer
20. A new matrix metalloproteinase inhibitor S1-27 induces apoptosis in several human myeloid leukemia cell lines and enhances sensitivity to TNF alpha-induced apoptosis
21. Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer
22. PI-88, a novel heparanase inhibitor and anti-angiogenic agent, interacts positively with cisplatin, paclitaxel, doxorubicin and gemcitabine in a syngeneic rat adenocarcinoma model
23. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin
24. Halofuginone: A potent inhibitor of critical steps in angiogenesis progression
25. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis
26. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma
27. Low molecular weight inhibitors of PAI-1 suppress tumour cell invasion and angiogenesis in vitro and reduce tumour growth in vivo
28. FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition
29. Clinical implications of circulating angiogenic factors in cancer patients
30. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
31. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data
32. Anti-VEGF antibody HuMV833: An EORTC biological treatment development group Phase I toxicity, pharmacokinetic and pharmacodynamic study
33. Phase II trial of single-agent rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer
34. GFB-116, a vascular endothelial growth factor (VEGF) binder, inhibits tumour growth and angiogenesis
35. NM3, an orally bioavailable small molecule inhibitor of VEGF expression inhibits xenograft tumor growth alone and enhances antitumor effects of standard chemotherapy
36. Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: Differential effect on proliferating endothelial cells
37. Progress in antiangiogenic gene therapy of cancer
38. A phase I/II study of repetitive dose angiozyme, a ribozyme targeting the Flt-1 receptor for VEGF
39. VEGF receptor signaling in tumor angiogenesis
40. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications
41. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies
42. A phase I pharmacokinetic and pharmacodynamic study of SU 5416 and doxorubicin in inflammatory breast cancer
43. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors
44. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: Time to take stock!
45. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation
46. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
47. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
48. A phase I study of ZD6474, an oral VEGF receptor tyrosine kinase inhibitor, in patients with solid tumours
49. CEP-5214, a novel orally active inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, inhibits VEGF-induced angiogenesis and prostate tumour growth in vivo
50. BIBF1000: A novel and potent VEGFR-2 inhibitor inhibits proliferation and induces apoptosis of endothelial cells in vitro
51. A novel low molecular weight VEGF-receptor binding inhibitor, VGA1102, inhibits the VEGF functions and growth of human tumour xenografts
52. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice
53. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas
54. The bacterial polysaccharide tecogalan blocks growth of breast cancer cells in vivo
55. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
56. 'Accidental' anti angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples
57. Protein kinase C inhibitors as novel anticancer drugs
58. Protein kinase A type I: A target for cancer therapy
59. Farnesyl transferase inhibitors: A novel targeted therapy for cancer
60. Targeting tumor angiogenesis with gene therapy
61. Fully humanised anti-IL-8 blocks angiogenesis and inhibits tumour growth of human melanoma cells
62. First results of a phase I trial of recombinant human angiostatin (RhA) by twice-daily subcutaneous injection in patients with advanced cancer
63. Tissue examination to monitor antiangiogenic therapy: A Phase I clinical trial with endostatin
64. A phase I safety and pharmacokinetic (PK) study of continuous intravenous (iv) rhEndostatin followed by subcutaneous (sc) administration in patients with advanced cancers
65. A Phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers
66. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti αvb3) antibody in patients with metastatic cancer
67. The endothelin-A receptor antagonist atrasentan (ABT 627) reduces skeletal remodelling activity in men with advanced hormone refractory prostate cancer
68. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer
69. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis
70. Tumstatin: An ECM-derived inhibitor of tumour growth and angiogenesis in response to combined hyperstimulation with bFGF, VEGF, and serum
71. Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model
72. Anginex, a newly designed peptide that inhibits angiogenesis
73. The alpha(v)-beta(3) inhibitor S247 decreases colon cancer metastasis, angiogenesis and improves survival in a murine model of liver metastasis
74. Reduction of colon cancer growth by a novel antiangiogenic agent that targets the integrin α5β1
75. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide
76. Phase I pharmacokinetic and toxicity study of weekly intravenous combrestatin A4 phosphate (CA4P)
77. Anti-tumour activity of vascular targeting agent ZD6126 is enhanced by split dose
78. Preclinical activity of the novel anti-vascular agent, pancratistatin phosphate
79. Mechanisms of tumour blood flow inhibition by the antitumour drug DMXAA(5,6-dimethylxanthenone-4-acetic acid
80. Current role of thalidomide in cancer treatment
81. A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
82. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma
83. The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells
84. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor
85. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma
86. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis
87. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
88. Tirapazamine: Prototype for a novel class of therapeutic agents targeting tumor hypoxia
89. Rational design and synthesis of novel thymidine phosphorylase inhibitors as anti-angiogenic agents
90. HSP90 as a new therapeutic target for cancer therapy: The story unfolds
91. Metronomic scheduling: The future of chemotherapy?
92. Redefining the target: Chemotherapeutics as antiangiogenics
93. Randomized, open-label, Phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
94. A Phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis
95. Angioprevention: Angiogenesis is a common and key target for cancer chemopreventive agents
96. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer
97. AngioDB: Database of angiogenesis and angiogenesis-related molecules
98. Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase